ScholarLens Back to search
2006•Вестник РОНЦ им. Н. Н. Блохина РАМНRequires access

Новые возможности терапии диссеминированного колоректального рака

К. С. Курилов, О В Жаркова, Е. Б. Миронова, Г К Жерлов, В. А. Хайленко, Lev Demidov, Т. А. Кузнецова, А. В. Сизинцев, С. В. Стражев, Vera Karaseva

Open publisher page 0 citations

Abstract

Efficacy of three chemotherapy regimens was studied in 99 patients with metastatic colorectal cancer. Patients receiving oxaliplatin plus capecitabine combination demonstrated better immediate and follow-up results than those receiving oxaliplatin + fluorouracil + folinic acid or fluorouracil + folinic acid regimens. Overall response and 2-year survival rates were 45.5±8.6%and19.1%respectivelyinoxaliplatinpluscapecit-8.6% and 19.1% respectively in oxaliplatin plus capecitabine group versus 40.6±8.7and16.3%respectivelyinthefluorouracil+folinicacidgroup.Differencesin.7 and 16.3% respectively in the fluorouracil + folinic acid group. Differences in survival rates between groups with vs without oxaliplatin were statistically significant (p

About this research paper

What this paper is about

Efficacy of three chemotherapy regimens was studied in 99 patients with metastatic colorectal cancer. Patients receiving oxaliplatin plus capecitabine combination demonstrated better immediate and follow-up results than those receiving oxaliplatin + fluorouracil + folinic acid or fluorouracil + folinic acid regimens. Overall response and 2-year survival rates were 45.5±8.6%and19.1%respectivelyinoxaliplatinpluscapecit-8.6% and 19.1% respectively in oxaliplatin plus capecitabine group versus 40.6±8.7and16.3%respectivelyinthefluorouracil+folinicacidgroup.Differencesin.7 and 16.3% respectively in the fluorouracil + folinic acid group. Differences in survival rates between groups with vs without oxaliplatin were statistically significant (p

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Efficacy of three chemotherapy regimens was studied in 99 patients with metastatic colorectal cancer. Patients receiving oxaliplatin plus capecitabine combination demonstrated better immediate and follow-up results than those receiving oxaliplatin + fluorouracil + folinic acid or fluorouracil + folinic acid regimens. Overall response and 2-year survival rates were 45.5±8.6%and19.1%respectivelyinoxaliplatinpluscapecit-8.6% and 19.1% respectively in oxaliplatin plus capecitabine group versus 40.6±8.7and16.3%respectivelyinthefluorouracil+folinicacidgroup.Differencesin.7 and 16.3% respectively in the fluorouracil + folinic acid group. Differences in survival rates between groups with vs without oxaliplatin were statistically significant (p

Key concepts: Folinic acid, Oxaliplatin, Capecitabine, Fluorouracil, Medicine, Colorectal cancer, Internal medicine, Chemotherapy

Back to paper searchBrowse research topicsOriginal source
Новые возможности терапии диссеминированного колоректального рака — Research Paper | ScholarLens